|
1
|
Chapman CJ, Thorpe AJ, Murray A,
Parsy-Kowalska CB, Allen J, Stafford KM, Chauhan AS, Kite TA,
Maddison P and Robertson JF: Immunobiomarkers in small cell lung
cancer: Potential early cancer signals. Clin Cancer Res.
17:1474–1480. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mamdani H, Induru R and Jalal SI: Novel
therapies in small cell lung cancer. Transl Lung Cancer Res.
4:533–544. 2015.PubMed/NCBI
|
|
3
|
Halazonetis TD, Gorgoulis VG and Bartek J:
An oncogene-induced DNA damage model for cancer development.
Science. 319:1352–1355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schvartzman JM, Sotillo R and Benezra R:
Mitotic chromosomal instability and cancer: Mouse modelling of the
human disease. Nat Rev Cancer. 10:102–115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goode EL, Ulrich CM and Potter JD:
Polymorphisms in DNA repair genes and associations with cancer
risk. Cancer Epidemiol Biomarkers Prev. 11:1513–1530.
2002.PubMed/NCBI
|
|
6
|
Yaglom JA, McFarland C, Mirny L and
Sherman MY: Oncogene-triggered suppression of DNA repair leads to
DNA instability in cancer. Oncotarget. 5:8367–8378. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scott SP and Pandita TK: The cellular
control of DNA double-strand breaks. J Cell Biochem. 99:1463–1475.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jeggo PA and Löbrich M: How cancer cells
hijack DNA double-strand break repair pathways to gain genomic
instability. Biochem J. 471:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Helleday T, Petermann E, Lundin C, Hodgson
B and Sharma RA: DNA repair pathways as targets for cancer therapy.
Nat Rev Cancer. 8:193–204. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pleasance ED, Stephens PJ, O'Meara S,
McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman
C, et al: A small-cell lung cancer genome with complex signatures
of tobacco exposure. Nature. 463:184–190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Byers LA, Wang J, Nilsson MB, Fujimoto J,
Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, et al:
Proteomic profiling identifies dysregulated pathways in small cell
lung cancer and novel therapeutic targets including PARP1. Cancer
Discov. 2:798–811. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Damia G and D'Incalci M: Targeting DNA
repair as a promising approach in cancer therapy. Eur J Cancer.
43:1791–1801. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hine CM, Seluanov A and Gorbunova V: Use
of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl
Acad Sci USA. 105:20810–20815. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Richardson C, Stark JM, Ommundsen M and
Jasin M: Rad51 overexpression promotes alternative double-strand
break repair pathways and genome instability. Oncogene. 23:546–553.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cox GA, Mahaffey CL, Nystuen A, Letts VA
and Frankel WN: The mouse fidgetin gene defines a new role for AAA
family proteins in mammalian development. Nat Genet. 26:198–202.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luke-Glaser S, Pintard L, Tyers M and
Peter M: The AAA-ATPase FIGL-1 controls mitotic progression, and
its levels are regulated by the CUL-3MEL-26 E3 ligase in
the C. elegans germ line. J Cell Sci. 120:3179–3187. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
L'Hôte D, Vatin M, Auer J, Castille J,
Passet B, Montagutelli X, Serres C and Vaiman D: Fidgetin-like1 is
a strong candidate for a dynamic impairment of male meiosis leading
to reduced testis weight in mice. PLoS One. 6:e275822011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yuan J and Chen J: FIGNL1-containing
protein complex is required for efficient homologous recombination
repair. Proc Natl Acad Sci USA. 110:10640–10645. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hartwell LH and Kastan MB: Cell cycle
control and cancer. Science. 266:1821–1828. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rajagopalan H and Lengauer C: Aneuploidy
and cancer. Nature. 432:338–341. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lupas AN and Martin J: AAA proteins. Curr
Opin Struct Biol. 12:746–753. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hanson PI and Whiteheart SW: AAA+
proteins: Have engine, will work. Nat Rev Mol Cell Biol. 6:519–529.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tucker PA and Sallai L: The AAA+
superfamily - a myriad of motions. Curr Opin Struct Biol.
17:641–652. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Snider J and Houry WA: AAA+ proteins:
Diversity in function, similarity in structure. Biochem Soc Trans.
36:72–77. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wendler P, Ciniawsky S, Kock M and Kube S:
Structure and function of the AAA+ nucleotide binding pocket.
Biochim Biophys Acta. 1823:2–14. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yachida S, Jones S, Bozic I, Antal T,
Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, et al:
Distant metastasis occurs late during the genetic evolution of
pancreatic cancer. Nature. 467:1114–1117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Heaphy CM, Bisoffi M, Joste NE,
Baumgartner KB, Baumgartner RN and Griffith JK: Genomic instability
demonstrates similarity between DCIS and invasive carcinomas.
Breast Cancer Res Treat. 117:17–24. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
O'Grady S, Finn SP, Cuffe S, Richard DJ,
O'Byrne KJ and Barr MP: The role of DNA repair pathways in
cisplatin resistant lung cancer. Cancer Treat Rev. 40:1161–1170.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Willers H, Azzoli CG, Santivasi WL and Xia
F: Basic mechanisms of therapeutic resistance to radiation and
chemotherapy in lung cancer. Cancer J. 19:200–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peters GJ, Avan A, Ruiz MG, Orsini V, Avan
A, Giovannetti E and Smit EF: Predictive role of repair enzymes in
the efficacy of Cisplatin combinations in pancreatic and lung
cancer. Anticancer Res. 34:435–442. 2014.PubMed/NCBI
|
|
31
|
Eastman A: The formation, isolation and
characterization of DNA adducts produced by anticancer platinum
complexes. Pharmacol Ther. 34:155–166. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hurwitz JL, McCoy F, Scullin P and Fennell
DA: New advances in the second-line treatment of small cell lung
cancer. Oncologist. 14:986–994. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Martin SA, Lord CJ and Ashworth A: DNA
repair deficiency as a therapeutic target in cancer. Curr Opin
Genet Dev. 18:80–86. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Madhusudan S and Middleton MR: The
emerging role of DNA repair proteins as predictive, prognostic and
therapeutic targets in cancer. Cancer Treat Rev. 31:603–617. 2005.
View Article : Google Scholar : PubMed/NCBI
|
